热门资讯> 正文
Fennec Pharmaceuticals发布了Pedmark（硫代硫酸钠注射液）2/3期STS-J 01试验的总体结果，该试验旨在减少日本儿科、青少年和年轻非转移性实体瘤患者中铂引起的耳毒性
2025-12-02 20:05
- Fennec Pharmaceuticals(FENC) 0
- FT Cboe Vest U.S. Equity Deep Buffer ETF - March(DMAR) 0
- Regis Corp.(RGS) 0
- Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK when Compared with Historically Reported Rates of Hearing Loss in Patients Receiving Cisplatin Alone (16-24% versus 56-63%, Respectively).
- PEDMARK Showed No Interference with Cisplatin Antitumor Activity as Evidenced by an Approximate 95% Clinical Response Rate.
- The Company Plans to Pursue Registration and is Exploring Partnering or Licensing Opportunities for PEDMARK® in Japan Based Upon These Results
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
